Risks of pharmaceutical supply chain disruptions from another pandemic or a Taiwan contingency are a growing concern, according to Minister Katsunobu Kato.
Few manufacturers — such as Japan’s Eisai and the U.S.’ Biogen — have continued to develop a treatment. We hope the health ministry announces the approval...